However, selinexor had similar effectiveness in all models, indicating the effectiveness of the drug is not dependent on baseline RNA levels of XPO1. Notably, biomarker studies of selinexor have not shown a direct relationship between efficacy and baseline XPO1 RNA expression in any investigated tumor type. This evidence concerns the gene XPO1 and neoplasm.